RecruitingPhase 2NCT07646626

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

A Phase II Study of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.

Enrollment

150 participants

Start Date

Jul 17, 2026

Study Type

INTERVENTIONAL

Conditions

Locally Advanced Unresectable or Metastatic Solid Tumors

Summary

This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SSGJ-612, a drug called SSGJ-705, and others for people with locally advanced unresectable or metastatic solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.